Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Renal Cell 23Neoplasms 14Neoplasm Metastasis 14Glioblastoma 14Prostatic Neoplasms 13Breast Neoplasms 11Brain Neoplasms 11Sarcoma 10Lymphoma, Non-Hodgkin 10Kidney Neoplasms 10Endometrial Neoplasms 10Melanoma 9Lymphoma, Mantle-Cell 9Gliosarcoma 8Multiple Myeloma 7Glioma 7Ovarian Neoplasms 6Carcinoma, Hepatocellular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Oligodendroglioma 5Lymphoma, Follicular 5Lymphoma 5Hodgkin Disease 5Central Nervous System Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 4Rhabdomyosarcoma 4

Interventions

Cyclophosphamide 8dinutuximab 7Magnetic Resonance Spectroscopy 7Topotecan 6Doxorubicin 6sargramostim 5Vincristine 5Stem Cell Transplantation 5Radiation 5Platinum 5Melphalan 5Isotretinoin 5Colony-Stimulating Factors 5Cisplatin 5Biopsy 51,2-diaminocyclohexaneplatinum II citrate 5Temozolomide 4Specimen Handling 4Irinotecan 4Etoposide 4Congresses as Topic 4Carboplatin 4Thiotepa 3Busulfan 33-Iodobenzylguanidine 3etoposide phosphate 2Razoxane 2Dexrazoxane 2temsirolimus 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ganglioneuroblastoma × temsirolimus × Clear all
NCT01767194 2022-10-24

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
73 enrolled 12 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡